Correction to “Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma”

S. Fetzko, A.A. Gupta, B.A. Setty, M.W. Malone, J. Schraw, P.J. Lupo, H. Russell, L. Nicholls, D. Walterhouse, D.S. Hawkins, and M.F. Okcu. Salvage Therapy Efficacy is Modified by Risk Group at Diagnosis in Patients With Relapsed Rhabdomyosarcoma. Pediatric Blood & Cancer 72, no. 3 (March 2025): e31477. https://doi.org/10.1002/pbc.31477. Epub 2024 Dec 9. PMID: 39654081.

In the revision process for our article, we changed the names of the two treatment groups and in Table 1, they were incorrectly labeled in reverse order. The titles for the treatment columns need to be corrected to:

The first column after “All Patients”: Currently “High Dose Alkylator Chemotherapy” needs to be corrected to “No High Dose Alkylator Chemotherapy”

The second column after “All Patients”: Currently “No High Dose Alkylator Chemotherapy” needs to be corrected to “High Dose Alkylator Chemotherapy”

We apologize for this error.